Aurelio Maggio

Dr. Aurelio Maggio

Campus of Haematology Franco e Piera Cutino, Foundation Franco and Piera Cutino, A.O.O.R. “Villa Sofia-Cervello”, 90146 Palermo, Italy
+1

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2002 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ACAdriana Ceci
Adriana Ceci
PBPaola Baiardi
Paola Baiardi
MFMariagrazia Felisi
Mariagrazia Felisi
MCMaria Domenica Cappellini
Maria Domenica Cappellini
VCVittorio Carnelli
Vittorio Carnelli
FTFernando Tricta
Fernando Tricta

1 March 2002 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
Aurelio MaggioAurelio Maggio
Aurelio Maggio
GDGennaro D'AMico
Gennaro D'AMico
AMAlberto Morabito
Alberto Morabito
MCMarcello Caprad
Marcello Caprad
CCCalogero Ciaccioe
Calogero Ciaccioe
MMMassimo Midirip
Massimo Midirip

27 March 2006 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
APAlessia Pepe
Alessia Pepe
Vincenzo PositanoVincenzo Positano
Vincenzo Positano
Maria Filomena SantarelliMaria Filomena Santarelli
Maria Filomena Santarelli
FSFortunato Sorrentino
Fortunato Sorrentino
ECEliana Cracolici
Eliana Cracolici
MLMassimo Lombardi
Massimo Lombardi

11 December 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CBCaterina Borgna-Pignatti
Caterina Borgna-Pignatti
GVGianluca Vergine
Gianluca Vergine
TLTuri Lombardo
Turi Lombardo
MCMaria Domenica Cappellini
Maria Domenica Cappellini
PCPaolo Cianciulli
Paolo Cianciulli
MBMaria Grazia Bisconte
Maria Grazia Bisconte
Summary: Hepatocellular carcinoma (HCC) frequently complicates hepatic cirrhosis secondary to viral infection or iron overload. Therefore, patients affected by thalassaemia syndromes have a theoretically high risk of developing the tumour. We collected data on patients attending Italian centres for the treatment of thalassaemia. Twenty‐two cases of HCC were identified; 15 were male. At diagnosis, the mean age was 45 ± 11 years and the mean serum ferritin was 1764 ± 1448 μg/l. Eighty‐six percent had been infected by hepatitis C virus. Nineteen of 22 cases were diagnosed after 1993, suggesting that this problem is becoming more frequent with the aging population of thalassaemia patients.

30 September 2010 in Haematologica
Verified
Journal Article
Open access
PDF file
APA. Pepe
A. Pepe
AMA. Meloni
A. Meloni
MCM. Capra
M. Capra
PCP. Cianciulli
P. Cianciulli
LPL. Prossomariti
L. Prossomariti
Aurelio MaggioAurelio Maggio
Aurelio Maggio
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. Design and Methods From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalassemia major patients who had been receiving one chelator alone for longer than one year. We identified three groups of patients: 24 treated with deferasirox, 42 treated with deferiprone and 89 treated with desferrioxamine. Myocardial iron concentrations were measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Liver iron concentrations were measured by T2* multiecho technique. Results The global heart T2* value was significantly higher in the deferiprone (34±11ms) than in the deferasirox (21±12 ms) and the desferrioxamine groups (27±11 ms) (P=0.0001). We found higher left ventricular ejection fractions in the deferiprone and the desferrioxamine versus the deferasirox group (P=0.010). Liver iron concentration, measured as T2* signal, was significantly lower in the desferrioxamine versus the deferiprone and the deferasirox group (P=0.004). Conclusions The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treated with oral deferasirox or subcutaneous desferrioxamine.

25 June 2009 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
ARAnna Ramazzotti
Anna Ramazzotti
APAlessia Pepe
Alessia Pepe
Vincenzo PositanoVincenzo Positano
Vincenzo Positano
GRGiuseppe Rossi
Giuseppe Rossi
DMDaniele De Marchi
Daniele De Marchi
MLMassimo Lombardi
Massimo Lombardi